PMC7154231_01
Timeline of 18F-FDG PET-CT findings, tracked with a pembrolizumab regimen and other diagnostic testing modalities. A transient intracardiac 18F-FDG avidity focal point on PET-CT is indicated by white arrows.
cro-0013-0212-g01.jpg
PMC7154231_01_cro-0013-0212-g01.jpg
F1
Two subsequent interim PET-CT scans, spaced 2 months apart, also did not reveal intracardiac FDG avidity; however, 9 months into treatment, his PET-CT showed a recurrent focus of FDG avidity in the left ventricle at the same site as initially noted despite continuing response at other metastatic sites (Fig. 1).